About Lehe
乐于心,和与众,与己乐,与人和; 心宽念纯,百病无生。
Leave your message or request below and we will get back to you as soon as possible.
We are conducting a clinical study on vNKT immunotherapy. This form is for preliminary screening only; saving it does not mean enrollment. Information is used for screening only; separate informed consent will be signed before formal enrollment.
Tip: For extensive records, you may contact the clinical study coordinator to submit pathology, imaging, or discharge summaries.
Abstract
Recognized more than a decade ago, NKT cells differentiate from mainstream thymic precursors through instructive signals emanating during TCR engagement by CD1d-expressing cortical thymocytes. Their semi-invariant αβ TCRs recognize isoglobotrihexosylceramide, a mammalian glycosphingolipid, as well as microbial α-glycuronylceramides found in the cell wall of Gram-negative, lipopolysaccharide-negative bacteria. This dual recognition of self and microbial ligands underlies innate-like antimicrobial functions mediated by CD40L induction and massive Th1 and Th2 cytokine and chemokine release. Through reciprocal activation of NKT cells and dendritic cells, synthetic NKT ligands constitute promising new vaccine adjuvants. NKT cells also regulate a range of immunopathological conditions, but the mechanisms and the ligands involved remain unknown. NKT cell biology has emerged as a new field of research at the frontier between innate and adaptive immunity, providing a powerful model to study fundamental aspects of the cell and structural biology of glycolipid trafficking, processing, and recognition.
Keyword(s): antigen presentation, CD1d, Ehrlichia, glycolipid, innate immunity, lymphocyte development, natural killer T cell, Salmonella, Sphingomonas, α-proteobacteria
Address: Room 1101 (Unit 101), 11th Floor, Building 1, No. 7 Courtyard, Kexueyuan Road, Life Science Park, Changping District, Beijing
Phone:010-8265 9866
Email:lehemedneo@hotmail.com
Scan to contact us